Diagnostic Performance of CO-RADS and the RSNA Classification System in Evaluating COVID-19 at Chest CT: A Meta-Analysis

Robert M. Kwee, MD PhD
Hugo J. A. Adams, MD PhD
Thomas C. Kwee, MD PhD

1 Department of Radiology, Zuyderland Medical Center, Heerlen/Sittard/Geleen, The Netherlands
2 Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
3 Department of Radiology, Nuclear Medicine and Molecular Imaging University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Correspondence
Robert M. Kwee, MD PhD
Department of Radiology, Zuyderland Medical Center
Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
Email: rmkwee@gmail.com

Original research

Authors disclosed no conflicts of interest.
Key Points

- Using the lowest clinically meaningful thresholds of CO-RADS of at least 3 and indeterminate according to the RSNA classification, sensitivity values were 92.5% and 90.2%, which implies that CO-RADS 1 and 2 and RSNA classification categories negative and atypical certainly do not exclude COVID-19.

- Using the highest thresholds of CORADS 5 and typical according to the RSNA classification, specificity values increased up to 93.1% and 94.9% at the cost of sensitivity, with values of 70.4% and 65.2, respectively.

Summary statement

- The frequency of coronavirus disease 2019 infection was higher in patients with higher CO-RADS and RSNA classification categories, which supports the order of grading used by both systems.

Abbreviations

CO-RADS = COVID-19 reporting and data system, COVID-19 = coronavirus disease 2019, RSNA = Radiological Society of North America, RT-PCR = real-time reverse-transcriptase–polymerase-chain-reaction
Abstract

Purpose
To determine the diagnostic performance of the COVID-19 Reporting and Data System (CO-RADS) and the Radiological Society of North America (RSNA) categorizations in patients with clinically suspected coronavirus disease 2019 (COVID-19) infection.

Materials and Methods
In this meta-analysis, studies from 2020, up to August 24, 2020 were assessed for inclusion criteria of studies that used CO-RADS or the RSNA categories for scoring chest CT in patients with suspected COVID-19. A total of 186 studies were identified. After review of abstracts and text, a total of nine studies were included in this study. Patient information (n, age, sex), CO-RADS and RSNA scoring categories, and other study characteristics were extracted. Study quality was assessed with the QUADAS-2 tool. Meta-analysis was performed with a random effects model.

Results
Nine studies (3283 patients) were included. Overall study quality was good, except for risk of non-performance of repeated reverse transcriptase polymerase chain reaction (RT-PCR) after negative initial RT-PCR and persistent clinical suspicion in four studies. Pooled COVID-19 frequencies in CO-RADS categories were: 1, 8.8%; 2, 11.1%; 3, 24.6%; 4, 61.9%; and 5, 89.6%. Pooled COVID-19 frequencies in RSNA classification categories were: negative 14.4%; atypical, 5.7%; indeterminate, 44.9%; and typical, 92.5%. Pooled pairs of sensitivity and specificity using CO-RADS thresholds were the following: at least 3, 92.5% (95% CI: 87.1, 95.7) and 69.2% (95% CI: 60.8, 76.4); at least 4, 85.8% (95% CI: 78.7, 90.9) and 84.6% (95% CI: 79.5, 88.5); and 5, 70.4% (95% CI: 60.2, 78.9) and 93.1% (95% CI: 87.7, 96.2). Pooled
pairs of sensitivity and specificity using RSNA classification thresholds for
indeterminate were 90.2% (95% CI: 87.5, 92.3) and 75.1% (95% CI: 68.9, 80.4) and
for typical were 65.2% (95% CI: 37.0, 85.7) and 94.9% (95% CI: 86.4, 98.2).

Conclusion
COVID-19 infection frequency was higher in patients categorized with higher CO-
RADS and RSNA classification categories.
Introduction

The coronavirus disease 2019 (COVID-19) pandemic has caused a major global crisis. On December 2, 2020, there were 64 million confirmed cases and almost 1.5 million confirmed deaths due to COVID-19 worldwide (1). Although most countries have already experienced the first surge of rising COVID-19 cases, second surges have started in late 2020. Chest imaging has an important role in the evaluation of patients with COVID-19 (2). The chest imaging findings of COVID-19 were first reported in January 2020 and included bilateral lung involvement and ground-glass opacities in the majority of hospitalized patients (3). Since this first report (3), several studies on the diagnostic value of chest CT in COVID-19 have been published. However, as most initial studies did not use uniform diagnostic criteria (4), their results cannot directly be translated to clinical practice.

Two major chest CT classification scales for standardized CT reporting of COVID-19 have been developed, namely the COVID-19 Reporting and Data System (CO-RADS) (5) and the Radiological Society of North America (RSNA) classification system for reporting COVID-19 pneumonia (6, 7). CO-RADS basically consists of five categories (CO-RADS 1 to 5; Table E1 and Figures E1-5 [supplement]), whereas the RSNA classification system consists of four categories (negative, atypical, indeterminate, and typical; Table E2 and Figures E1-5 [supplement]). CO-RADS and the RSNA chest CT classification system are very similar. CO-RADS categories 1, 2, 3-4, and 5 are essentially equal to categories negative, atypical, indeterminate, and typical of the RSNA classification system, respectively (5, 8). The use of these standardized diagnostic classification systems may reduce observer variation, enhance clinical communication, and improve generalizability. However, the diagnostic yields of both the CO-RADS and RSNA
categorizations are not completely clear yet. Original studies on this topic may suffer from small sample sizes and potential methodological quality concerns. Aggregated data are necessary to understand the clinical interpretability of these chest CT classification systems for the diagnosis of COVID-19. Although there have already been meta-analyses published on the diagnostic performance of chest CT in detecting COVID (4, 9), the initial studies included within these meta-analyses suffered from methodological quality issues and did not use uniform diagnostic criteria such as the CO-RADS and RSNA categorizations. These shortcomings limit translation of diagnostic performance values to clinical practice. Therefore, our objective was to determine, in a meta-analysis, the diagnostic performance of the CO-RADS and the RSNA classification system in patients with clinically suspected COVID-19 infection.

Materials and Methods

The study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline (10).

Data Sources

A search in MEDLINE and Embase was conducted to find original publications on the diagnostic performance of the CO-RADS and the RSNA classification systems in evaluating symptomatic with clinically suspected COVID-19 infection. The following search term was used: (CO-RADS OR CORADS OR Radiological Society of North America OR RSNA) AND (Corona OR Coronavirus OR Covid-19 OR SARS-Cov-2 OR 2019nCoV OR Wuhan-virus) AND (Computed tomography OR Computerized tomography OR CT OR CAT OR HRCT).
In addition, the journal Radiology: Cardiothoracic Imaging was manually searched for potentially relevant publications. Publications which cited the original CO-RADS (5) and RSNA classification system for reporting COVID-19 pneumonia (6, 7) were also searched using the cited reference function in Web of Science and MEDLINE. The search was updated until August 24, 2020.

Study Selection

Original studies which provided data on the diagnostic performance of the CO-RADS or RSNA classification system in evaluating patients with clinically suspected COVID-19 infection, and in which reverse transcription polymerase chain reaction (RT-PCR) was the reference standard, were eligible for inclusion. Reviews, abstracts, and studies were excluded for the following reasons: (a) included fewer than 10 patients, (b) reported insufficient data to compose a 2×2 contingency table to calculate sensitivity and specificity on per-patient level for any CO-RADS or RSNA classification system threshold, and (c) only provided data on the performance of artificial intelligence-based analyses. When overlapping data were presented in more than one study, the study with the largest number of patients was selected. Titles and abstracts of retrieved studies were reviewed using aforementioned selection criteria. The full-text version of each potentially eligible study was then reviewed to definitively determine if the study fulfilled the selection criteria.

Study Data Extraction

For each included study, the main characteristics (country of origin, patient inclusion period, number of patients, age, and sex of patients, clinical characteristics of included patients, CT protocol, CT interpreters, reference standard, and COVID-19 frequency)
were extracted by two independent reviewers (R.M.K., radiologist, and H.J.A., third-year resident in radiology). If data from multiple readers were reported, only data from the first reader were extracted and used for the analyses. The number of patients with and without COVID-19 according to the different CO-RADS and the RSNA classification categories was also extracted. Data on interobserver or intraobserver agreement using the CO-RADS and the RSNA classification system were also extracted. Any discrepancies were solved by consensus with a third reviewer (T.C.K., radiologist).

**Study Quality Assessment**

The quality of included studies was assessed by two independent reviewers (R.M.K. and H.J.A.) using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool, which comprises four key items: patient selection, index test, reference standard, and flow and timing (11). Any discrepancies were solved by consensus with a third reviewer (T.C.K.).

**Statistical Analyses**

Frequency of COVID-19 in each of the categories of the CO-RADS and the RSNA classification system were calculated for each individual study and pooled with a random effects model. Sensitivity and specificity of the CO-RADS and RSNA classification systems at specific diagnostic thresholds in detecting COVID-19 (ie, CO-RADS thresholds of at least 3, at least 4, 5, and RSNA classification thresholds indeterminate and typical) were pooled using a bivariate random-effects model (12). The numbers were pooled in each CORADS and in each RSNA classification category separately. The same random effects model was used per each study, across
different categories. Cochran's Q and Chi-squared tests were performed to test for heterogeneity between studies, which was defined as $P < .10$. Statistical analyses were performed using the Open Meta-Analyst software package (13) and Meta-analysis of Diagnostic Accuracy Studies package in R software (14, 15).

**Results**

**Literature Search**

Figure 1 displays the study selection process. A total of 182 studies were eligible for inclusion after searching databases. After screening titles and abstracts, 168 studies were excluded, leaving 14 studies that were potentially eligible for inclusion. After reading the full text of the 14 studies, three studies (16-18) were excluded because the diagnostic performance of either CO-RADS or the RSNA classification system was not investigated, one study (5) was excluded because no data on a per-patient level were reported, and another study (19) was excluded because there were overlapping data with another study (8) which comprised a larger number of patients. Nine studies were eventually included (8, 20-27).

The main study characteristics are shown in Table 1 and Table E3 (supplement). All assessed studies were performed between January and June 2020. The median number of patients per study was 312 (range, 71-859), and the total number of patients of all studies combined was 3283. All nine studies included patients with a clinical suspicion of COVID-19. The mean frequency of COVID-19 was 48.7% (range, 41.7–59.8%). Of all patients included in the nine studies, 1979 patients were evaluated with CO-RADS and 1400 patients were evaluated with the RSNA classification system.
Figure 2 provides a summary of the QUADAS-2 quality assessments. In one study (20), it was unclear whether patients were enrolled consecutively or randomly. There was no risk of bias with regard to patient selection in the other studies or with regard to index test. Risk of bias with respect to reference test was rated high in three studies (23, 26, 27) because repeated RT-PCR testing was not used in all patients with a negative initial RT-PCR result and persistent clinical suspicion of COVID-19. Risk of bias with respect to reference test was rated unclear in one study (21), because it was not clear whether all patients with an initial negative RT-PCR result and a persistent clinical suspicion of COVID-19 underwent repeated RT-PCR testing. In one study (20), there was potential risk of bias with regard to flow and timing, because the time interval between CT and RT-PCR testing was not reported. There was no risk of bias with regard to flow and timing in the other studies, because the maximum time interval between chest CT and RT-PCR did not exceed seven days (22). There were no applicability concerns.

**Diagnostic Performance of CO-RADS**

The frequency of COVID-19 in each of the categories of CO-RADS is displayed in Table 2. With higher CO-RADS classification, the frequency of COVID-19 increased. Pooled frequency of COVID-19 in CO-RADS categories 1, 2, 3, 4, and 5 were 8.8%, 11.1%, 24.6%, 61.9%, and 89.6%. Pooled sensitivity and specificity of the CO-RADS and the RSNA classification system at specific thresholds are displayed in Table 3. Pooled pairs of sensitivity and specificity using CO-RADS thresholds were the following: at least 3, 92.5% (95% CI: 87.1, 95.7) and 69.2% (95% CI: 60.8, 76.4); at least 4, 85.8% (95% CI: 78.7, 90.9) and 84.6% (95% CI: 79.5, 88.5); and 5, 70.4% (95% CI: 60.2, 78.9) and 93.1% (95% CI: 87.7, 96.2).
Diagnostic Performance of the RSNA Classification System

The frequency of COVID-19 in each of the categories of the RSNA classification systems is displayed in Table 4. With higher RSNA classification, the frequency of COVID-19 increased. Pooled frequencies of COVID-19 in RSNA classification categories negative, atypical, indeterminate, and typical were 14.4%, 5.7%, 44.9%, and 92.5%. Pooled sensitivity and specificity of the RSNA classification system at specific thresholds are displayed in Table 5. Pooled pairs of sensitivity and specificity using RSNA classification thresholds were the following: indeterminate, 90.2% (95% CI: 87.5, 92.3) and 75.1% (95% CI: 68.9, 80.4) and typical, 65.2% (95% CI: 37.0, 85.7) and 94.9% (95% CI: 86.4, 98.2).

Interobserver and intraobserver agreement

For the CO-RADS, substantial to almost perfect interobserver agreement has been reported, with $\kappa$ values of 0.648 to 0.773 (8) and intraclass correlation coefficients of 0.800 to 0.874 (20). For the RSNA classification system, moderate to substantial interobserver agreement has been reported, with $\kappa$ values of 0.500 (23) and of 0.570 to 0.663 (8). None of the included studies reported data on intraobserver agreement.

Discussion

This meta-analysis provides pooled data with regard to the frequency of patients with COVID-19 for each category of CO-RADS and the RSNA classification system in patients with clinically suspected with having a COVID-19 infection. With higher CO-RADS and RSNA classification category, the frequency of patients with COVID-19 increased. This supports the order of grading that is used by both systems. In CO-
RADS 5, the prevalence of COVID-19 was 89.6%. In the RSNA category typical, the frequency of COVID-19 was 92.5%. We also provided sensitivity and specificity values for specific diagnostic thresholds. Using the lowest clinically meaningful thresholds of CO-RADS of at least 3 and indeterminate according to the RSNA classification, sensitivity values were 92.5% (95% CI: 87.1, 95.7%) and 90.2% (95% CI: 87.5, 92.3%), respectively. These findings imply that CO-RADS 1 and 2 and RSNA classification categories negative and atypical do not exclude COVID-19. Furthermore, when using these low diagnostic thresholds, specificity is only moderate with values of 69.2% (95% CI: 60.8, 76.4) for CO-RADS of at least 3 and 75.1% (95% CI: 68.9, 80.4%) for RSNA indeterminate. If higher diagnostic thresholds are applied, specificity naturally increases at the cost of sensitivity. Using CO-RADS of at least 5 and the RSNA classification typical as diagnostic thresholds, specificity values increased up to 93.1% (95% CI: 87.7, 96.2) and 94.9% (95% CI: 86.4, 98.2). However, when using these high diagnostic thresholds, sensitivity is only moderate with values of 70.4% (95% CI: 60.2, 78.9) and 65.2% (95% CI: 37.0, 85.7).

Methodological quality of the studies included in the current meta-analysis generally appears to have higher quality than studies included within prior meta-analyses (4, 9). In two prior meta-analyses, high risk of bias was present in all six included studies (100%) (4) and in ten of thirteen included studies (77%) (9). In our current meta-analysis, the "reference standard" was the only QUADAS-2 item which was deemed to be of high risk of bias. This item applied to three of the nine included studies (33%) because repeated RT-PCR testing was not used in all patients with a negative initial RT-PCR result and persistent clinical suspicion of COVID-19 (23, 26, 27).
Importantly, we provide a meta-analysis that specifically focused on the diagnostic performance of chest CT in COVID-19 by selecting studies that used standardized diagnostic criteria. Therefore, our study results are more generalizable and useful to clinical practice compared to other prior meta-analyses on CT for COVID-19 assessment. Our finding that CO-RADS 1 and 2 and RSNA classification categories negative and atypical do not exclude COVID-19 are in line with the results of a meta-analysis in nearly 3500 patients, which reported an estimated frequency of 10.6% for normal chest CT findings in symptomatic patients with COVID-19 (28). In a prior meta-analysis of six studies which did not use uniform diagnostic criteria, pooled sensitivity and specificity were 94.6% (95% CI: 91.9, 96.4) and 46.0% (95% CI: 31.9, 60.7), respectively (4). Using CO-RADS of at least 3 and RSNA classification indeterminate as diagnostic thresholds, similar sensitivity values of 92.5% (95% CI: 87.1, 95.7) and 90.2% (95% CI: 87.5, 92.3) can be achieved, while relatively higher specificity values of 69.2% (95% CI: 60.8, 76.4) and 75.1% (95% CI: 68.9, 80.4) are obtained. Thus, when using CO-RADS or the RSNA classification system instead of non-standardized criteria, it appears that specificity may be improved without sacrificing sensitivity.

If a low threshold is being used (e.g., any lung abnormality on chest CT is considered positive for COVID-19), virtually all COVID-19 cases with lung abnormalities will be correctly classified, but all non-COVID-19 cases with any lung abnormality at chest CT will be incorrectly classified as having COVID-19 (29). By applying standardized diagnostic criteria such as CO-RADS or the RSNA classification system, a higher proportion of non-COVID-19 cases with lung abnormalities due to other lung diseases will be correctly classified as not having COVID-19 but an alternative lung disease. It should be noted that the studies in our
In press meta-analysis included patients between January and June 2020, a period with a high COVID-19 frequency (mean of 48.7%; range, 41.7–59.8%). Specificity is likely to decrease with lower COVID-19 frequency and increasing frequency of other viral lung infections such as influenza (30).

Our study has some limitations. First, the included studies used RT-PCR, which is an imperfect reference standard with a reported sensitivity of 89% (95% CI: 81, 94) (31). Sensitivity of RT-PCR appears to be lower in elderly patients (31), which may be due to sampling error in these patients who are more likely to have poorer performance status (26). Furthermore, vendor-specific effects and differences in the quality assurance process may affect the performance of RT-PCR (31). However, RT-PCR is still the recommended method to confirm current COVID-19 infection (32-34). Second, because of the relatively low number of included studies, we did not perform subgroup or meta-regression analyses to explain statistical heterogeneity between studies. Geographical differences, non-reported prevalence of other lung diseases, interobserver variability in chest CT assessment, RT-PCR performance, and some methodological quality issues may have been potential sources of heterogeneity. Note that interobserver agreement varies from substantial to almost perfect for the CO-RADS (8, 20) and from moderate to substantial for the RSNA classification system (8, 23).

In conclusion, COVID-19 infection frequency was higher in patients categorized with higher CO-RADS and RSNA classification categories. Our data may be useful for deciding on the probability of COVID-19 based on chest CT (along with clinical information and RT-PCR).
References

1. Johns Hopkins University School of Medicine. CORONAVIRUS RESOURCE CENTER. https://coronavirus.jhu.edu/. Updated June 13, 2020August 24, 2020.

2. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, Schluger NW, Volpi A, Yim JJ, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo JM, Humbert M, Inoue Y, Kauczor HU, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN. The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner Society. Chest 2020;158(1):106-116. doi: 10.1016/j.chest.2020.04.003

3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5

4. Adams HJA, Kwee TC, Yakar D, Hope MD, Kwee RM. Systematic Review and Meta-Analysis on the Value of Chest CT in the Diagnosis of Coronavirus Disease (COVID-19): Sol Scientiae, Illustra Nos. AJR Am J Roentgenol 2020:1-9. doi: 10.2214/AJR.20.23391

5. Prokop M, van Everdingen W, van Rees Vellinga T, Quarles van Ufford H, Stoger L, Beenen L, Geurts B, Gietema H, Krdzalic J, Schaefer-Prokop C, van Ginneken B, Brink M, Society C-SRWGotDR. CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19-Definition and Evaluation. Radiology 2020;296(2):E97-E104. doi: 10.1148/radiol.2020201473
6. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, Henry TS, Kanne JP, Kligerman S, Ko JP, Litt H. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. Radiology: Cardiothoracic Imaging 2020.

7. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, Henry TS, Kanne JP, Kligerman S, Ko JP, Litt H. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA - Secondary Publication. J Thorac Imaging 2020;35(4):219-227. doi: 10.1097/RTI.0000000000000524

8. De Jaegere TM, Krdzalic J, Fasen BA, Kwee RM. Radiological Society of North America Chest CT Classification System for Reporting COVID-19 Pneumonia: Interobserver Variability and Correlation with RT-PCR. Radiology: Cardiothoracic Imaging;2(3).

9. Suchá D, Van Hamersvelt RW, van den Hoven AF, de Jong PA, Verkooijen HM. Suboptimal Quality and High Risk of Bias in Diagnostic Test Accuracy Studies on Chest Radiography and Computed Tomography in the Acute Setting of the COVID-19 Pandemic: A Systematic Review. Radiology: Cardiothoracic Imaging 2020. doi: doi: 10.1148/ryct.2020200342

10. PRISMA. Transparent reporting of systematic reviews and meta-analyses. http://www.prisma-statement.org/. Updated 2015August 24, 2020.

11. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, Group Q-. QUADAS-2: a revised tool for the
quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155(8):529-536. doi: 10.7326/0003-4819-155-8-201110180-00009

12. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58(10):982-990. doi: 10.1016/j.jclinepi.2005.02.022

13. OpenMeta[Analyst]. http://www.cebm.brown.edu/openmeta/. August 24, 2020.

14. The R Project for Statistical Computing. https://www.r-project.org/. August 24, 2020.

15. Mada-package. https://www.rdocumentation.org/packages/mada/versions/0.5.8/topics/mada-package. August 24, 2020.

16. Byrne D, O'Neill SB, Muller NL, Silva Muller CI, Walsh JP, Jalal S, Parker W, Bilawich AM, Nicolaou S. RSNA Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19: Interobserver Agreement Between Chest Radiologists. Can Assoc Radiol J 2020:846537120938328. doi: 10.1177/0846537120938328

17. Lang M, Som A, Mendoza DP, Flores EJ, Li MD, Shepard JO, Little BP. Detection of Unsuspected Coronavirus Disease 2019 Cases by Computed Tomography and Retrospective Implementation of the Radiological Society of North America/Society of Thoracic Radiology/American College of Radiology Consensus Guidelines. J Thorac Imaging 2020. doi: 10.1097/RTI.0000000000000542

18. Adams SJ, Dennie C. Chest imaging in patients with suspected COVID-19. CMAJ 2020;192(25):E676. doi: 10.1503/cmaj.200626
19. Kwee RM, Krdzalic J, Fasen B, de Jaegere TMH, Group C-CIS-ENS. CT Scanning in Suspected Stroke or Head Trauma: Is it Worth Going the Extra Mile and Including the Chest to Screen for COVID-19 Infection? AJNR Am J Neuroradiol 2020;41(7):1165-1169. doi: 10.3174/ajnr.A6607

20. Fujioka T, Takahashi M, Mori M, Tsuchiya J, Yamaga E, Hori T, Yamada H, Kimura M, Kimura K, Kitazume Y, Kishino M, Tateishi U. Evaluation of the Usefulness of CO-RADS for Chest CT in Patients Suspected of Having COVID-19. Diagnostics (Basel) 2020;10(9). doi: 10.3390/diagnostics10090608

21. De Smet K, De Smet D, Ryckaert T, Laridon E, Heremans B, Vandenbulcke R, Demedts I, Bouckaert B, Grayspeerdts S, Martens GA. Diagnostic Performance of Chest CT for SARS-CoV-2 Infection in Individuals with or without COVID-19 Symptoms. Radiology 2020;202708. doi: 10.1148/radiol.2020202708

22. Falaschi Z, Danna PSC, Arioli R, Pasche A, Zagaria D, Percivale I, Tricca S, Barini M, Aquilini F, Andreoni S, Carriero A. Chest CT accuracy in diagnosing COVID-19 during the peak of the Italian epidemic: A retrospective correlation with RT-PCR testing and analysis of discordant cases. Eur J Radiol 2020;130:109192. doi: 10.1016/j.ejrad.2020.109192

23. Ciccarese F, Coppola F, Spinelli D, Galletta GL, Lucidi V, Paccapelo A, De Benedittis C, Balacchi C, Golfieri R. Diagnostic Accuracy of North America Expert Consensus Statement on Reporting CT Findings in Patients with Suspected COVID-19 Infection: An Italian Single Center Experience. Radiology: Cardiothoracic Imaging 2020;2(4). doi: doi: 10.1148/ryct.2020200312

24. Hermans JJR, Groen J, Zwets E, Boxma-De Klerk BM, Van Werkhoven JM, Ong DSY, Hanselaar W, Waals-Prinzen L, Brown V. Chest CT for triage during COVID-
19 on the emergency department: myth or truth? Emerg Radiol 2020. doi: 10.1007/s10140-020-01821-1

25. Korevaar DA, Kootte RS, Smits LP, van den Aardweg JG, Bonta PI, Schinkel J, Vigeveno RM, van den Berk IAH, Scheerder MJ, Lemkes BA, Goorhuis A, Beenen LFM, Annema JT, Amsterdam UMC. Added value of chest computed tomography in suspected COVID-19: an analysis of 239 patients. Eur Respir J 2020;56(2). doi: 10.1183/13993003.01377-2020

26. Miranda Magalhaes Santos JM, Paula Alves Fonseca A, Pinheiro Zarattini Anastacio E, Formagio Minenelli F, Furtado de Albuquerque Cavalcanti C, Borges da Silva Teles G. Initial Results of the Use of a Standardized Diagnostic Criteria for Chest Computed Tomography Findings in Coronavirus Disease 2019. J Comput Assist Tomogr 2020. doi: 10.1097/RCT.0000000000001054

27. Dofferhoff ASM, Swinkels A, Sprong T, Berk Y, Spanbroek M, Nabuurs-Franssen MH, Vermaat M, van de Kerkhof B, Willekens MHC, Voss A. [Diagnostic algorithm for COVID-19 at the ER]. Ned Tijdschr Geneeskd 2020;164.

28. Adams HJA, Kwee TC, Yakar D, Hope MD, Kwee RM. Chest CT Imaging Signature of Coronavirus Disease 2019 Infection: In Pursuit of the Scientific Evidence. Chest 2020. doi: 10.1016/j.chest.2020.06.025

29. Adams HJA, Kwee TC, Kwee RM. Coronavirus Disease 2019 and Chest CT: Do Not Put the Sensitivity Value in the Isolation Room and Look Beyond the Numbers. Radiology 2020;297(1):E236-E237. doi: 10.1148/radiol.2020201709

30. Altmayer S, Zanon M, Pacini GS, Watte G, Barros MC, Mohammed TL, Verma N, Marchiori E, Hochhegger B. Comparison of the computed tomography findings in COVID-19 and other viral pneumonia in immunocompetent adults: a systematic review and meta-analysis. Eur Radiol 2020. doi: 10.1007/s00330-020-07018-x
31. Kim H, Hong H, Yoon SH. Diagnostic Performance of CT and Reverse Transcriptase Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis. Radiology 2020;296(3):E145-E155. doi: 10.1148/radiol.2020201343

32. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. https://www.who.int/publications/i/item/10665-331501. Updated March 19, 2020

33. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19. https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19. Updated April 8, 2020

34. National Institute for Public Health and the Environment. Testing for COVID-19. Updated August 17, 2020
**Figure legends**

**Figure 1.** Flow diagram of study selection. The asterisk indicates that there were duplicate studies.
Figure 2. Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) quality assessments of included studies.
# Table 1. Main Characteristics of the Included Studies

| Study | Country  | Inclusion period | No. Patients (males) | Age | Inclusion clinical characteristics | COVID-19 frequency |
|-------|----------|------------------|----------------------|-----|------------------------------------|--------------------|
| **A. CO-RADS** | | | | | | |
| Fujioka et al. (20) | Japan | Jan- Jun | 154 (101) | 61.3 (21-93) | Symptomatic patients who were suspected by a clinician of having COVID-19 based on symptoms and history of exposure. | 49.4% (76/154) |
| De Smet et al. (21) | Belgium | Mar 19- to Apr 20 | 859 (443) | by sex | WHO-listed symptoms of COVID-19 pneumonia | 41.7% (358/859) |
| Hermans et al. (24) | Netherlands | Mar 27- Apr 20 | 319 (157) | range 44-75 | Suspected infection with COVID-19 in combination with at least one of the following† | 41.7% (133/319) |
| Korevaar et al. (25) | Netherlands | Mar 16- Apr 16 | 239 (139) | median, 63 (IQR 51-71) | Suspected COVID-19‖ | 52.7% (126/239) |
| **B. RSNA** | | | | | | |
| Falaschi et al. (22) | Italy | Mar 3- Apr 9 | 773 (424) | 62.4 (16-100) | Suspected for COVID-19§ | 59.8% (462/773) |
| Ciccarese et al. (23) | Italy | Feb 27- Mar 27 | 460 (267) | 54 (14-97) | Suspected with COVID-19 pneumonia‖ | 45.9% (211/460) |
| Magalhães Santos et al. (26) | Brazil | Mar 13- Mar 23 | 71 (33) | 47.2 (8-94) | Patients who fulfilled the clinical criteria for confirmed COVID-19 ⁴ | 50.7% (36/71) |
| Dofferhoff et al. (27) | Netherlands | Mar 8- Mar 31 | 312 (168) | 64 (18-94) | Patients with fever of unknown origin and patients with recent respiratory symptoms with or without fever | 49.4% (154/312) |
| **C. CO-RADS and RSNA** | | | | | | |
| de Jaegere et al. (8) | Netherlands | Mar 12- Mar 23 | 96 (61) | median 70 (range 29-94) | Clinical suspicion of COVID-19 (i.e. fever, cough, and/or shortness of breath) | 46.9% (45/96) |

Note.— The year for all inclusion dates are in 2020; months and days of the month are shown. Age shown as mean (range) unless otherwise specified.

Time interval indicates the time interval between symptom onset and chest CT. CT protocol, time between symptom onset and CT, and information about image interpreters are shown in Table E1 (supplement). COVID-19 = coronavirus disease 2019, IQR = interquartile range
Males had median age of 71 years (interquartile range, 54-80) and females had median age of 68 years (interquartile range, 51-82).

† Criteria were 1) new respiratory symptoms persisting for less than 2 weeks and present during the last 24 hours, 2) saturation of less than 94% and/or respiration rate of greater than 20/min and/or abdominal complaints, and 3) a high clinical suspicion even in the absence of symptoms.

‡ Criteria were those with 1) fever, 2) cough or dyspnea, or 3) other signs suggestive of COVID-19 (eg gastro-intestinal symptoms).

§ Criteria were when one or more of these conditions were met: 1) presence of fever (ie, temperature≥37.5 °C), cough and dyspnea; 2) presence of mild symptoms and ascertained close contact with a confirmed COVID-19 patient; 3) one previously positive laboratory test result.

‖ Criteria were patients presenting with fever (of unknown origin) or respiratory symptoms
Table 2. Frequency of COVID-19 in each of the Categories of CO-RADS

| Study                        | CO-RADS 1      | CO-RADS 2      | CO-RADS 3      | CO-RADS 4      | CO-RADS 5      |
|------------------------------|----------------|----------------|----------------|----------------|----------------|
| Fujioka et al. (20)*         | 18.0% (9/50)   | 28.6% (6/21)   | 69.2% (9/13)   | 75.0% (12/16)  | 90.9% (40/44)  |
| De Smet et al. (21)          | 8.6% (27/313)  | 13.5% (12/89)  | 19.5% (15/77)  | 36.8% (25/68)  | 89.4% (279/312)|
| Hermans et al. (24)          | 6.1% (6/99)    | 9.4% (3/32)    | 9.1% (4/44)    | 64.5% (20/31)  | 90.1% (100/111)|
| Korevaar et al. (25)†        | 5.9% (4/68)    |                | 17.2% (5/29)   | 82.4% (117/142)|
| de Jaegere et al. (8)†       | 11.1% (1/9)    | 3.1% (1/32)    | 38.5% (5/13)   | 76.9% (10/13)  | 96.6% (28/29)  |
| Dofferhoff et al. (27)       | 10.2% (9/88)   | 14.3% (3/21)   | 19.4% (6/31)   | 63.0% (17/27)  | 82.1% (119/145)|
| Pooled frequency‡            | 8.8% (6.2, 11.4)| 11.1% (4.3, 18.0)| 24.6% (12.8, 36.5)| 61.9% (45.0-78.7)| 89.6% (85.6, 93.7)|
| P-value for heterogeneity§   | .35            | .048           | < .001         | < .001         | .04            |

Note.— The 95% CI is shown within parenthesis for the pooled frequency.

* Data from the first reader.
†CO-RADS categories 1 and 2, and CO-RADS categories 4 and 5 were merged
‡CO-RADS 1, 2, 4, and 5 data from the study of Korevaar et al. (25) were not included in the pooled analysis.
§Statistical heterogeneity between studies was defined as $P<0.10$. 
### Table 3. Pooled Sensitivity and Specificity at Specific Thresholds According to CO-RADS

| Study                    | Threshold CO-RADS ≥ 3                           | Threshold CO-RADS ≥ 4                           | Threshold CO-RADS 5                           |
|--------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                          | Sensitivity (95% CI)                             | Sensitivity (95% CI)                             | Sensitivity (95% CI)                             |
|                          | Specificity (95% CI)                             | Specificity (95% CI)                             | Specificity (95% CI)                             |
|                          |                                                  |                                                  |                                                  |
| Fujioka et al. (20)      | 68.4% (57.3, 77.8%)                             | 68.4% (57.3, 77.8%)                             | 52.6% (41.6, 63.5%)                             |
|                          | 88.2% (78.5, 93.9%)                             | 88.2% (78.5, 93.9%)                             | 94.1% (85.8, 97.7%)                             |
| De Smet et al. (21)      | 84.9% (80.8, 88.3%)                             | 84.9% (80.8, 88.3%)                             | 77.9% (73.4, 81.9%)                             |
|                          | 84.8% (81.4, 87.7%)                             | 84.8% (81.4, 87.7%)                             | 93.4% (90.9, 95.3%)                             |
| Hermans et al. (24)      | 90.2% (84.0, 94.2%)                             | 90.2% (84.0, 94.2%)                             | 75.2% (67.2, 81.8%)                             |
|                          | 88.2% (82.7, 92.1%)                             | 88.2% (82.7, 92.1%)                             | 94.1% (89.7, 96.7%)                             |
| Korevaar et al. (25)     | 92.9% (87.0, 96.2%)                             | 92.9% (87.0, 96.2%)                             | No data available                               |
|                          | 77.9% (69.4, 84.5%)                             | 77.9% (69.4, 84.5%)                             | No data available                               |
| de Jaegere et al. (8)    | 84.4% (71.2, 92.3%)                             | 92.2% (81.5, 96.9%)                             | 62.2% (47.6, 74.9%)                             |
|                          | 92.2% (81.5, 96.9%)                             | 92.2% (81.5, 96.9%)                             | 98.0% (89.7, 99.7%)                             |
| Dofferhoff et al. (27)   | 88.3% (82.3, 92.5%)                             | 77.2% (70.1, 83.1%)                             | 77.3% (70.0, 83.2%)                             |
|                          | 88.3% (82.3, 92.5%)                             | 77.2% (70.1, 83.1%)                             | 83.5% (77.0, 88.5%)                             |
| Pooled values*           | 92.5% (87.1, 95.7%)                             | 69.2% (60.8, 76.4%)                             | 70.4% (60.2, 78.9%)                             |
|                          | 69.2% (60.8, 76.4%)                             | 85.8% (78.7, 90.9%)                             | 93.1% (87.7, 96.2%)                             |
|                          |                                                  | 84.6% (79.5, 88.5%)                             |                                                  |
|                          |                                                  | 70.4% (60.2, 78.9%)                             |                                                  |

*For the pooled analysis, data from the first readers from the study of Fujioka et al. (20) and De Jaegere et al. (8) and were used.

Note.— Values in parenthesis are the 95% CIs.

* For the pooled analysis, data from the first readers from the study of Fujioka et al. (20) and De Jaegere et al. (8) and were used.
† Statistical heterogeneity between studies was defined as $P < .10$. 
Table 4. Frequency of COVID-19 in Each of the Categories of the RSNA Classification System

| Study                          | Negative       | Atypical       | Indeterminate | Typical        |
|--------------------------------|----------------|----------------|---------------|----------------|
| Falaschi et al. (22)           | 14.9% (43/288)*| 86.3% (419/485)*|               |                |
| Ciccarese et al. (23)          | 13.8% (17/123) | 10.4% (7/67)   | 36.7% (36/98) | 87.8% (151/172)|
| Magalhães Santos et al. (26)   | 15.0% (3/20)   | 0.0% (0/14)    | 30.0% (3/10)  | 96.8% (30/31)  |
| de Jaegere et al. (8)†         | 25.0% (2/8)    | 3.2% (1/31)    | 64% (25/39)   | 96.4% (17/18)  |
| Pooled frequency‡              | 14.4% (8.8, 19.9) | 5.7% (0.9, 10.4) | 44.9% (24.1, 65.7) | 92.5% (86.1, 98.9) |
| * P-value for heterogeneity§   | .77            | .29            | .007          | .07            |

* RSNA classification categories negative and atypical, and RSNA classification categories indeterminate and typical were merged.
† Data from the first reader.
‡ Data from the study of Falaschi et al. (22) were not included in the pooled analysis.
Statistical heterogeneity between studies was defined as $P < .10$. 
Table 5. Pooled Sensitivity and Specificity at Specific Thresholds According to the RSNA Classification System.

| Study                      | Threshold Indeterminate | Threshold typical |
|----------------------------|-------------------------|-------------------|
|                            | Sensitivity | Specificity | Sensitivity | Specificity |
| Falaschi et al. (22)       | 90.7% (87.7, 93.0%) | 78.8% (73.9-83.0) | No data available | No data available |
| Ciccarese et al. (23)      | 88.6% (83.6, 92.2%) | 69.3% (63.5-74.5) | 71.6% (65.1, 77.2) | 71.6% (65.1, 77.2) |
| Magalhães Santos et al. (26)| 91.7% (78.2, 97.1%) | 80.5% (66.0, 89.8) | 83.3% (68.1, 92.1) | 97.4% (86.8-99.5) |
| de Jaegere et al. (8)      | 93.3% (82.1, 97.7%) | 73.7% (61.0, 83.4) | 37.8% (25.1, 52.4) | 98.0% (89.7-99.7) |
| Pooled values*             | 90.2% (87.5, 92.3%) | 75.1% (68.9, 80.4) | 65.2% (37.0, 85.7) | 94.9% (86.4-98.2) |
| $P$-value for heterogeneity$^\dagger$ | .73            | .05                | <.001          | .13               |

Note.— Values in parenthesis are the 95% CIs.

* For the pooled analysis, data from reader 1 from the study of De Jaegere et al. (8) were used.

$^\dagger$ Statistical heterogeneity between studies was defined as $P < .10$.
Supplemental Figures

Figure E1. Example of CO-RADS 1 and atypical appearance according to the RSNA classification in a 55-year-old female patient with increasing dyspnea. Axial chest CT images at the level of the heart (A, containing some motion artifact) and trachea (B) show diffuse smooth interlobular septal thickening (arrows pointing to representative examples), pleural effusion (asterisk in A), and cardiomegaly (A). Findings are compatible with congestive heart failure.
Figure E2. Example of CO-RADS 2 and atypical appearance according to the RSNA classification in a 41-year-old man with dyspnea and fever. Axial chest CT image shows consolidations with air bronchograms in both lower lobes (arrows), consistent with lobar pneumonia. There is pleural effusion on the left (asterisk). No ground-glass opacities were present.

Figure E3. Example of CO-RADS 3 and indeterminate appearance according to the RSNA classification in a 57-year-old woman with dyspnea. Axial chest CT image shows aspecific perihilar ground-glass opacity on the right (arrow). No other obvious lung abnormalities were present.
**Figure E4.** Example of CO-RADS 4 and indeterminate appearance according to the RSNA classification in a 57-year-old woman with dyspnea and fever. Axial chest CT image shows bilateral ground-glass opacities in a predominant peribronchovascular distribution (arrows). There is no clear contact between the ground-glass opacities and the visceral pleura.

**Figure E5.** Example of CO-RADS 5 and typical appearance according to the RSNA classification in a 52-year-old man with cough and shortness of breath. Axial chest

CT image shows bilateral multifocal ground-glass opacities which are peripherally located, in lung regions close to visceral pleural surfaces (arrows).
### Supplemental Tables

#### Table E1. CO-RADS (adopted from reference (5)).

| CO-RADS category | Level of suspicion | CT findings |
|------------------|--------------------|-------------|
| 1                | Very low           | Normal CT findings or CT findings of unequivocal non-infectious etiology, including emphysema, perifissural nodules, lung tumors, fibrosis, and interstitial pulmonary edema (such as in congestive heart failure). |
| 2                | Low                | CT findings in the lungs that are typical of infectious etiology that are considered not compatible with COVID-19. Examples are bronchitis, infectious bronchiolitis, bronchopneumonia, lobar pneumonia, and pulmonary abscess. Features include tree-in-bud sign, a centrilobular nodular pattern, lobar or segmental consolidation, and lung cavitation. |
| 3                | Intermediate       | Equivocal findings for pulmonary involvement of COVID-19 based on CT features that can also be found in other viral pneumonias or non-infectious etiologies. Findings include perihilar ground-glass, homogenous extensive ground glass with or without sparing of some secondary pulmonary lobules, or ground glass together with smooth interlobular septal thickening with or without pleural effusion in absence of other typical CT findings. Small ground-glass opacities that are not |
centrilobular or not located close to the visceral pleura are also included.

|   | High  | CT findings that are typical for COVID-19 but showing some overlap with other (viral) pneumonias. Findings are similar to CO-RADS 5 but are not located in contact with the visceral pleura or are located strictly unilaterally, are in a predominant peribronchovascular distribution, or are superimposed on severe diffuse pre-existing pulmonary abnormalities. |
|---|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5 | Very high | Typical CT findings. Obligatory features are ground-glass opacities, with or without consolidations, close to visceral pleural surfaces, including the fissures, and a multifocal bilateral distribution. |
**Table E2.** RSNA classification system for reporting COVID-19 pneumonia (adopted from reference (6, 7)).

| COVID-19 pneumonia imaging classification | Rationale | CT Findings |
|------------------------------------------|-----------|-------------|
| Typical appearance                       | Commonly reported imaging features of greater specificity for COVID-19 pneumonia | Peripheral, bilateral, GGO* with or without consolidation or visible intralobular lines (“crazy-paving”) |
|                                          |           | Multifocal GGO of rounded morphology with or without consolidation or visible intralobular lines (“crazy-paving”) |
|                                          |           | Reverse halo sign or other findings of organizing pneumonia (seen later in the disease) |
| Indeterminate appearance                 | Nonspecific imaging features of COVID-19 pneumonia | Absence of typical features AND Presence of: |
|                                          |           | Multifocal, diffuse, perihilar, or unilateral GCO with or without consolidation lacking a specific distribution and are non-rounded or non-peripheral. |
| Atypical appearance | Uncommonly or not reported features of COVID-19 pneumonia | Absence of typical or indeterminate features AND Presence of: Isolated lobar or segmental consolidation without GGO Discrete small nodules (centrilobular, “tree-in-bud”) Lung cavitation Smooth interlobular septal thickening with pleural effusion |
|---------------------|----------------------------------------------------------|---------------------------------------------------------------|
| Negative for pneumonia | No features of pneumonia | No CT features to suggest pneumonia |

*GGO = ground-glass opacity.*
Table E3. Additional information on included studies

| Study                  | CT protocol                                      | CT interpreter(s)                                                                 | Time interval                  |
|------------------------|--------------------------------------------------|----------------------------------------------------------------------------------|--------------------------------|
| Fujioka et al. (20)    | Unenhanced multi-detector CT with 1 mm, 1.25 mm, or 5 mm slice thickness | 2 radiologists and 2 radiology residents                                          | Mean of 8.6 days (range 0-27)  |
| De Smet et al. (21)    | Unenhanced MDCT with 1 mm or 1.25 mm slice thickness | 2 cardiothoracic radiologists with 24 and 9 years of experience, in consensus      | Not reported                    |
| Falaschi et al. (22)   | Unenhanced MDCT with 1 mm slice thickness         | Two radiologists with more than 10 years of experience in thoracic imaging, in consensus | Not reported                    |
| Ciccarese et al. (23)  | Unenhanced MDCT with 1 mm or 1.25 mm slice thickness | Two radiologists with more than 10 years and 1 year of experience in thoracic imaging | Not reported                    |
| Hermans et al. (24)    | Unenhanced multi-detector CT                      | 20 radiologists who were trained to use the CO-RADS classification. Two independent radiologists were consulted in case of any doubt about the classification. | ≤2 weeks                       |
| Korevaar et al. (25)   | Unenhanced multi-detector CT                      | Attending radiologists, with varying degrees of experience. Second reading was performed in some cases by a dedicated acute radiologist. | Median of 7 days (interquartile range 3-10) |
| Magalhães Santos et al. (26) | Unenhanced MDCT                          | Two radiologists with 11 and 4 years of experience in chest imaging            | Not reported                    |
| de Jaegere et al. (8)  | Unenhanced MDCT with 1 mm slice thickness       | 2 chest radiologists with 5 and 22 years of experience in chest CT interpretation, and by a fifth-year radiology resident | Median of 7 days (range 2-21)  |
| Dofferhoff et al. (27) | Not reported                                    | 1 radiologist                                                                  | Not reported                    |